One Amgen Center Drive
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
Tweets by Amgen
The Amgen Difference
1786 articles with Amgen
The fund will be administered through the Ventura County Community Foundation. Officials indicate that 100 percent of the funds will go to help victims’ families. The Foundation is calling for additional donations.
Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
Additional Data Analyzing Treatment Patterns in the United States Shows Underutilization of LDL-C Lowering Treatments in At-Risk Patients and Need for Improved Patient Awareness of Treatment Goals
New Pledge is in Addition to $250,000 Contribution to Ventura County Community Foundation's Conejo Valley Victims Fund
The pharma industry began to push back against the presidential blueprint for drug prices ahead of the election. Will that continue with a now divided Congress?
Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018
Amgen (NASDAQ:AMGN) today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER-1 study, evaluating the long-term safety and efficacy of Repatha®
Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
Amgen today announced that new clinical data will be presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018.
Amgen Foundation Deepens Commitment To Aspiring Scientists Worldwide By Expanding Amgen Scholars Program
Through a new $21 Million, Four-Year Investment, Amgen Scholars Program to Reach Additional 1,500 Undergraduates
The U.S. Food and Drug Administration (FDA) gave the green light to Hyrimoz, a biosimilar to AbbVie’s blockbuster drug Humira, five years ahead of the time it can be launched in U.S. markets.
10/31/2018It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.
Amgen today announced financial results for the third quarter of 2018
Shares of Ann Arbor, Mich.-based Esperion Therapeutics are up more than 7 percent in premarket trading after the company announced on Sunday that planned to seek regulatory approval for its cholesterol-lowering therapy that hit the mark in a Phase III trial.
Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease
Repatha Results in Consistent Reductions in LDL-C Levels and Cardiovascular Events in Patients Independent of Kidney Function
Amgen today announced that it will report its third quarter 2018 financial results on Tuesday, Oct. 30, 2018, after the close of the U.S. financial markets.
Thousand Oaks-based Amgen will reduce the price of its anti-cholesterol drug Repatha by 60 percent to $5,850 per year as part of a move to improve affordability by lowering patient copays, the company announced Wednesday.
First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate
mgen (NASDAQ:AMGN) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel
Amgen (NASDAQ: AMGN) today announced that it is making Repatha® (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price of $5,850 per year.
Amgen today announced that its Board of Directors declared a $1.32 per share dividend for the fourth quarter of 2018.
10/19/2018TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.